Endpoints News
Corxel is the second drug developer in two weeks to choose a blank-check merger to go public, a route that had fallen out of favor.
Recap by typeshit. Full story at Endpoints News.
The EMA's CHMP amended its type 2 diabetes indication, and Italian diabetologists say Italy could be the first European country to offer the once-weekly combo.
26:19
A personal update from TakingWeightOff on life after stopping tirzepatide, three weeks in, and what caught them off guard.
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
A history of drug advertising, from opium-laced tonics and Radithor to the 1938 law after Elixir Sulfanilamide killed over 100 people. Semaglutide is mostly a hook.
8:51
Regan Archibald takes on a common question from people using retatrutide: whether the tiredness some report wears off.
The retatrutide rival from United Biotechnology led to weight loss of up to 9.8% at 24 weeks in 211 Chinese adults, beating semaglutide's 4.8%, per Cell Metabolism.
Loading…